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Sir,
With the introduction of next generation sequencing into
research and the clinic, geneticists now face the problem of
variant interpretation in single cases, which is a challenging
task due to the lack of data from additional affected family
members. For the majority of the variants in our genome
we do not know whether they are damaging and patho-
genic or just harmless rare polymorphisms. We therefore
must rely heavily on in silico prediction programs and the
information found in large genetic databases such as ExAC
[Exome Aggregation Consortium (ExAC), Cambridge, MA]
(http://exac.broadinstitute.org) to predict the pathogenicity
of variants. The letter from Pedroso et al. (2016) addresses
this problem.
Pedroso et al. (2016) state that many of the reported
SCA23 mutations in PDYN are present in ExAC and sug-
gest that this brings into question the validity of PDYN as
the disease-causing gene for SCA23. They point out that
the SCA23 mutations were detected in 37 of 60 700 indi-
viduals in ExAC, a database that was founded in 2014, 4
years after our original SCA23 report was published, when
none of these PDYN variations had been detected in con-
trols or any genetic database, supporting our conclusion
that PDYN is the SCA23 disease gene. ExAC combines
multi-ethnic sequencing data from several sources, as it in-
cludes sequencing studies on heart disease, type 2 diabetes,
schizophrenia, bipolar disorder, and Tourette’s syndrome,
besides projects such as 1000 Genomes. This means that
ExAC clearly must contain disease-causing variants and by
definition does not represent the genetic background of the
general population, and this may be reflected in higher
minor allele frequencies than anticipated for SCA23.
SCA23 prevalence reflects only those patients who have
been diagnosed with the disease in a population, and are
hard to establish given the rarity of the disease.
Occurrences of mutations within a population database
could reflect everyone who will ever get the disease, includ-
ing individuals not yet diagnosed and those who will never
get a proper diagnosis. Finally, the ExAC browser does not
contain clinical information, and the browser disclaimer
clearly states it cannot fully exclude the possibility of
some samples being of a cancerous origin. Clearly there
are very valid reasons to question using ExAC to exclude
variations in a gene as being causative.
Pedroso et al. also claim all reported PDYN variants to be
disease-causing, which is not true. We clearly mention in the
work described in Jezierska et al. (2013), and not in Fogel
et al. (2012) as claimed by Pedroso et al. (2016), that the
c.616C4T, p.Arg206Cys variant (MAF ExaC; 0.0001318)
and the c.617G4A, p.Arg206His variant might well be
rare polymorphisms as the p.Arg206Cys variant did not
have any effect on processing of PDYN, and no co-segrega-
tion could be detected for p.Arg206His (Jezierska et al.,
2013). Therefore, we did not conclude that these variants
exhibit pathogenic effects. Indeed, we are quite conservative
about reporting pathogenicity for variants that are not re-
ported in ExAC, such as the p.Gly227Asp variant, or for
variants that have not shown pathogenicity in functional
validation studies, such as the p.Arg206Cys variant. Our
work clearly showed that we do not address pathogenicity
solely by using in silico predictions and database screening,
but deliver substantial functional evidence (Bakalkin et al.,
2010; Jezierska et al., 2013; Smeets et al., 2015).
Recently, we have clearly demonstrated that mutant
PDYN causes SCA23 (Smeets et al., 2015). Mice expressing
PDYN with the p.Arg212Trp mutation exhibited gait def-
icits at 3 months of age and general loss of motor coord-
ination and Purkinje cell loss at 12 months of age,
recapitulating the symptoms of SCA23 patients accurately.
These effects were not seen in mice expressing wild-type
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PDYN. Furthermore, while PDYN is widely expressed in
the CNS, the expression of mutant PDYN only causes cere-
bellar pathology in mice, just like SCA23 patients, mimick-
ing human SCA23 pathology in detail.
Pedroso et al. point out that loss-of-function and missense
mutations are well tolerated in the heterozygous state. This
does not, however, exclude PDYN as the disease-causing gene
for an autosomal dominant disease such as SCA23. A Fisher’s
exact test displayed significant enrichment of PDYN variants
in ataxia cases (P = 0.0238), indicating that PDYN sequence
variation—including loss-of-function and missense muta-
tions—is not well tolerated (Jezierska et al., 2013). This indi-
cates an increased genetic burden of PDYN in ataxia cases,
and clearly contradicts the statement of Pedroso et al.
Additionally, the majority of mutations reported for SCA23
are missense mutations, while Pedroso et al. deemed them
loss-of-function mutations. Mutations are only categorized
as loss-of-function after functional validation of the vari-
ant—thereby validating pathogenicity. Notably, in autosomal
dominant disorders, most missense mutations exhibit a gain-
of-function rather than a loss (Roberts et al., 2007; Liu et al.,
2010; Giudicessi et al., 2011; Wemho¨ner et al., 2015), and
we have demonstrated a gain-of-function for several of the
SCA23 mutations using the increase in dynorphin A peptide
levels as the outcome measure (Bakalkin et al., 2010;
Jezierska et al., 2013; Smeets et al., 2015).
Furthermore, prior to the identification of PDYN as the
SCA23 gene, we sequenced many likely candidate genes in
the two-point linkage analysis interval but did not detect
any mutations (Verbeek, 2009). The odds that a gene in
this region other than PDYN contains a variation that
could cause SCA are extremely low, and these odds are
reduced to zero by our validation studies. Recently,
MacArthur et al. (2014) published guidelines for establish-
ing causality of variants causing human disease and our
work on PDYN meets important criteria to this end,
namely (i) detection of segregation of the p.Ser138Arg vari-
ant in a large Dutch pedigree; (ii) identification of multiple
independent SCA families carrying additional mutations in
PDYN; and (iii) experimental validation of the predicted
damaging impact of candidate variants in cell models and
a mouse model (Bakalkin et al., 2010; Jezierska et al.,
2013; Smeets et al., 2015).
In conclusion, our original genetic study and comprehen-
sive functional studies (Bakalkin et al., 2010; Jezierska et
al., 2013; Smeets et al., 2015) demonstrate that PDYN is
the SCA23 disease gene. The fact that we published valid-
ation studies of PDYN variants that did not show a dama-
ging effect indicates that we (i) do not solely rely on in
silico predictions and databases to determine pathogenicity
of a novel variation; and (ii) do not report all identified
variations as pathogenic. While we agree with Pedroso et
al. that genetic variations should be thoroughly functionally
validated before they are reported as disease-causing, and
reported variations without functional validation should be
critically reviewed, we do not agree that this is the case for
PDYN and SCA23.
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